National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011
Open Access
- 24 June 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 68 (11) , 2626-2631
Abstract
As recommended by the French ANRS programme for the surveillance of HIV-1 resistance, we estimated the prevalence of transmitted drug resistance-associated mutations (RAMs) in antiretroviral-naive, chronically HIV-1-infected patients. RAMs were sought in samples from 661 newly diagnosed HIV-1-infected patients in 2010/11 at 36 HIV clinical care centres. Weighted analyses were used to derive representative estimates of the percentage of patients with RAMs. At patient inclusion, the prevalence of virus with protease (PR) or reverse transcriptase (RT) RAMs was 9.0% (95% CI 6.8%–11.2%). No integrase RAMs were observed. The prevalences of protease inhibitor, nucleoside RT inhibitor and non-nucleoside RT inhibitor RAMs were 1.8%, 6.2% and 2.4%, respectively. Resistance to one, two and three classes of antiretroviral agent was observed in 7.9%, 0.9% and 0.2% of patients, respectively. The frequency of RAMs was higher in patients infected with B compared with non-B subtype virus (11.9% versus 5.1%, P = 0.003). Baseline characteristics (gender, age, country of transmission, CD4 cell count and viral load) were not associated with the prevalence of transmitted RAMs. However, men having sex with men (MSM) were more frequently infected with resistant virus than were other transmission groups (12.5% versus 5.8%, P = 0.003). Compared with the 2006/07 survey, the overall prevalence of resistance remained stable. However, a significant decrease in the frequency of virus with PR RAMs was observed in 2010/11 compared with the 2006/07 survey (1.8% versus 5.0%, P = 0.003). In France in 2010/11, the global prevalence of transmitted drug-resistant variants was 9.0%, and the prevalence was stable compared with the 2006/07 survey. MSM and B subtype-infected patients are the groups with a higher prevalence of drug resistance.Keywords
This publication has 18 references indexed in Scilit:
- Sentinel Surveillance of HIV-1 Transmitted Drug Resistance, Acute Infection and Recent InfectionPLOS ONE, 2011
- Transmission Clustering Drives the Onward Spread of the HIV Epidemic Among Men Who Have Sex With Men in QuebecThe Journal of Infectious Diseases, 2011
- Transmitted Drug Resistance in the CFAR Network of Integrated Clinical Systems Cohort: Prevalence and Effects on Pre-Therapy CD4 and Viral LoadPLOS ONE, 2011
- Low-Frequency HIV-1 Drug Resistance Mutations and Risk of NNRTI-Based Antiretroviral Treatment FailureJAMA, 2011
- Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in FranceJournal of Antimicrobial Chemotherapy, 2010
- Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 UpdatePLOS ONE, 2009
- A public health model for the molecular surveillance of HIV transmission in San Diego, CaliforniaAIDS, 2009
- Preexisting Resistance to Nonnucleoside Reverse‐Transcriptase Inhibitors Predicts Virologic Failure of an Efavirenz‐Based Regimen in Treatment‐Naive HIV‐1–Infected SubjectsThe Journal of Infectious Diseases, 2008
- Population-Based Sequencing of the V3 Region of env for Predicting the Coreceptor Usage of Human Immunodeficiency Virus Type 1 QuasispeciesJournal of Clinical Microbiology, 2007
- Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infectionJournal of Antimicrobial Chemotherapy, 2007